Trial Profile

A pivotal phase II trial assessing CT041for the treatment of patients with Claudin18.2 (CLDN18.2) positive advanced gastric /gastroesophageal junction cancer (GC/GEJ) who have failed at least 2 prior lines of systemic therapies

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Aug 2024 Status changed from recruiting to active, no longer recruiting, as per CARsgen media release.
24 Aug 2022 According to a CARsgen media release, the company plans to submit an NDA to the NMPA in China in the first half of 2024.
23 Mar 2022 According to a CARsgen media release, the company has completed the first patient enrollment in the study at the Beijing Cancer Hospital.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com